Vice President, Development Innovations
Carol serves as the Vice President for Sarah Cannon Development Innovations and European Operations. Her responsibilities include overseeing Sarah Cannon's CRO, Development Innovations and also leading the UK Drug Development Program. She is responsible for shaping the company’s vision for global collaborations both from a site and a CRO perspective in Europe.
Woodward joined Sarah Cannon in 2016 and has more than 20 years of drug development experience in hematology and oncology research. She received her master’s degree from the University of Wales in England in 1999. Before joining Sarah Cannon Research Institute, she was the Vice President of Hematology/Oncology Global Project Management at PPD and prior to that worked on drug research and development at Shire Pharmaceuticals.
Senior Director, Clinical Affairs
Paula Benge serves as the senior director of clinical affairs for Sarah Cannon Development Innovations. In her role, she directs and oversees the clinical affairs department, which includes a team of line managers, clinical team leads, clinical research associates, site activation specialists and clinical project associates. She has more than 25 years of experience in various roles in the pharmaceutical industry and clinical research organizations. She has served in various capacities in quality assurance, regulatory affairs and clinical operations. While in clinical operations, she served in roles ranging from a Clinical Research Associate to various management roles providing oversight for teams managing trials for sponsors. Prior to joining Sarah Cannon, she worked for Eli Lilly and Company and Quintiles. She graduated with a bachelor’s of science degree in biology from James Madison University.
Senior Director, Clinical Development
Carol Greenlees serves as senior director of clinical development for Sarah Cannon Development Innovations. In her role, she oversees and manages clinical development collaborations with select pharmaceutical partners. She joined Sarah Cannon in 2010 with more than 18 years of drug development experience working primarily in project management, operations and clinical development roles in the biotech sector. Previously, she was the head of European clinical development for Antisoma Research Ltd. and director of European clinical operations for CV Therapeutics Ltd. She received her PhD in pharmacology from The University of Glasgow in the UK.
Director, Clinical Development
Tracey Hammett currently serves as director, clinical development for Sarah Cannon Development Innovations. In her role, she leads cross-functional teams to design and deliver programs and projects with Pharma partners. She also serves as an alliance lead, working to improve processes and standards. She has more than 22 years of experience in drug development. Prior to joining Sarah Cannon, Hammett served as a clinical delivery director at AstraZeneca Pharmaceuticals. She has a degree in nursing from the Oxford School of Nursing in the UK.
Janet Karlix, PharmD
Director, Medical & Clinical Science
Dr. Karlix serves as director of medical & clinical science for Sarah Cannon Development Innovations. Dr. Karlix has more than 25 years of experience in drug development and clinical trials, specifically in immunotherapeutics with an emphasis on pharmacokinetics, pharmacodynamics and pharmacogenomics. Prior to joining Sarah Cannon, she served as vice president of clinical services at Exhale, Inc. Dr. Karlix also served as medical director of immunotherapy, gastroenterology and neurology and the national director for field medical teams at Élan Pharmaceuticals, Inc., and played a key role in developing the first FDA directed REMS program.
Dr. Karlix previously served as a tenured professor at the University of Florida and director of translational clinical research and trials. She earned her bachelors of science and PharmD from Purdue University College of Pharmacy. She completed an ASHP-accredited clinical residency at Medical College of Virginia and immunology/oncology residency at University of Texas in San Antonio.
Sheetal Khedkar, MBBS, MSPH
Senior Director, Regulatory Science
Dr. Khedkar serves as senior director of regulatory science for Sarah Cannon Development Innovations. In her role, Dr. Khedkar is responsible for developing and maintaining collaborative relationships with key stakeholders including academic and pharma partners in oncology research. She is a physician with over 15 years of experience in the healthcare industry. Dr. Khedkar graduated from Mahatma Gandhi Medical College in Bombay, India, received her MSPH at Meharry Medical College in Nashville, Tenn., and completed her post-doctoral fellowship at Vanderbilt University in breast cancer research. Before joining Sarah Cannon in 2008, Dr. Khedkar served as senior researcher at the Vanderbilt Institute for Global Health and as a faculty member at University of Phoenix. She also served as the Head of Americas for Lifecycle Safety at Quintiles.
Christopher Morley, MPH
Director, Clinical Development
Christopher Morley serves as a director of clinical development for Sarah Cannon Development Innovations. Blending program and asset management with Sponsor relationship management, he oversees molecule portfolios through planning, execution, oversight and governance on behalf of Sponsors. He has worked more than 17 years in the clinical research industry, with the majority of his time in global oversight and project management at contract research organizations in multiple oncology and hematology indications. Prior to joining Sarah Cannon, Morley served as global project director at inVentiv Health Clinical. He has also worked for several CROs including PPD, Inc., PAREXEL International and PRA Health Sciences, as well as worked internationally. He has a master’s degree in public health from Emory University Rollins School of Public Health.
Kim Futch, MBA
Director, Clinical Development
Kim Futch joined Sarah Cannon Development Innovations in 2019 as director, clinical development. In this role, she leads and supports client relationships driving clinical development strategies and program delivery for key compounds and studies within a partner's portfolio. With more than 18 years of drug development experience in large pharma, biotech and CROs, Futch has focused expertise in oncology clinical development, operations and medical informatics leading programs from early phase through successful global registrations. She has a BS in Neuroscience from Lafayette College and an MBA in Pharmaceutical Business from The University of the Sciences in Philadelphia.
Senior Director, Data Science
Tracy Parker is the senior director of data science for Sarah Cannon Development Innovations. In her role, she oversees biostatistics and statistical programming for the CRO. She has more than 15 years of clinical research experience including oversight in data management, data programming, biostatistics, statistical programming and medical writing. Prior to joining Sarah Cannon, she was the associate director of strategic resourcing and CRO relationship manager for a large pharma strategic partnership with inVentiv Health Clinical. She received her undergraduate degree in mathematics from the University of North Carolina in Charlotte and her MBA from the University of North Carolina in Wilmington.
Donald K. “D.K.” Strickland, MD
Vice President, Medical and Clinical Science
Dr. Strickland serves as the vice president of medical and clinical science for Sarah Cannon Development Innovations. In his role, he oversees the design and conduct of clinical research for studies in oncology and hematology. Dr. Strickland joined Sarah Cannon in 2013 with extensive clinical research and drug development experience in early through late phase trials. He received his bachelor’s degree and medical degree from the University of Missouri-Kansas City. After completing pediatrics and chief residency at Children’s Mercy Hospital, he completed a fellowship in hematology and oncology at Duke University Medical Center. Prior to joining Sarah Cannon, Dr. Strickland held positions in academic and private practice, as well as in the bio-oncology and CRO sectors. He is board certified in pediatric hematology-oncology.